In a 31-year-old woman on Yasmin (drospirenone/ethinyl estradiol) and spironolactone, why are total testosterone, free testosterone, estradiol, and progesterone all low, and what should be done to assess for underlying androgen excess or for fertility planning?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

The Low Hormone Levels Are Expected and Caused by Your Medications

Your low testosterone, estradiol, and progesterone levels are the direct pharmacological result of taking Yasmin (ethinyl estradiol/drospirenone) combined with spironolactone—this is exactly what these medications are designed to do. These findings do not indicate a new underlying problem; they reflect successful suppression of your endogenous hormone production by your current regimen 1.

Why Your Hormones Are Suppressed

Combined Oral Contraceptives Suppress All Sex Hormones

Yasmin works by:

  • Suppressing ovulation through inhibition of gonadotropin-releasing hormone, FSH, and LH 1
  • Reducing ovarian androgen production dramatically 2, 3
  • Increasing sex hormone-binding globulin (SHBG), which binds up free testosterone 1
  • Blocking the androgen receptor through drospirenone's antiandrogenic activity 4, 1

The ethinyl estradiol in Yasmin suppresses your natural estradiol production by shutting down the hypothalamic-pituitary-ovarian axis. Your measured estradiol of <15 pg/mL reflects the absence of ovarian estradiol production—the synthetic ethinyl estradiol you're taking cannot be measured by standard estradiol assays 1.

Similarly, progesterone levels of 1.5 ng/mL are expected because you're not ovulating (no corpus luteum formation). The drospirenone provides progestogenic activity but is not measured as progesterone 1.

Spironolactone Adds Additional Androgen Suppression

Spironolactone further:

  • Directly inhibits testosterone secretion 5
  • Blocks androgen binding to the androgen receptor 5, 4
  • May have estrogenic activity 5

The combination of Yasmin plus spironolactone creates profound androgen suppression, explaining your total testosterone of 35 ng/dL and free testosterone of 2 (units unclear, but clearly suppressed) 2, 3, 6.

What You Should Do Now

If You Have No Symptoms and Don't Want Pregnancy

Continue your current regimen without changes. Your hormone levels, while low, are the intended therapeutic effect. The guidelines emphasize that oral contraceptives are first-line therapy for managing hyperandrogenism, and adding spironolactone is appropriate for enhanced androgen blockade 4, 7.

Monitor for:

  • Symptoms of estrogen deficiency (hot flashes, vaginal dryness, bone health concerns with long-term use)
  • Mood changes or sexual dysfunction
  • Breakthrough bleeding patterns

If You're Planning Pregnancy or Want to Assess Baseline Hormones

You must stop both medications for at least 2-3 months before hormone testing 8. The guidelines are explicit that accurate androgen assessment requires:

  • No hormonal contraceptives for adequate washout period
  • Testing during days 1-7 of a natural menstrual cycle
  • Use of a laboratory proficient in low-level androgen measurement, preferably LC-MS/MS 8, 9, 10

Your previous elevated testosterone is likely still present but completely masked by your medications. The AACE guidelines warn that many women are given oral contraceptives to "regulate menstrual cycles" without proper determination of the source of hyperandrogenism 8.

If You Have Concerning Symptoms

Evaluate for:

  • Bone health: Long-term suppression of estradiol to <15 pg/mL raises concerns about bone density, though the synthetic ethinyl estradiol should provide some protection
  • Cardiovascular risk factors: Yasmin with drospirenone carries higher VTE risk than second-generation progestins 11, 12
  • Metabolic parameters: Check fasting glucose, lipids, blood pressure 7, 13
  • Potassium levels: Both drospirenone and spironolactone have antimineralocorticoid activity; hyperkalemia risk exists, especially with renal impairment 1

Critical Pitfalls to Avoid

Do not interpret these hormone levels as indicating ovarian failure, premature menopause, or adrenal insufficiency. This is iatrogenic suppression, not pathology. The synthetic hormones you're taking (ethinyl estradiol and drospirenone) are providing hormonal activity that cannot be measured by standard assays 1.

Do not add exogenous testosterone or DHEA while on this regimen. One study attempted DHEA supplementation with drospirenone-containing COCs and found it negated the beneficial effects on acne without consistent improvements in sexual function 14.

Do not assume your original hyperandrogenism is "cured." If you had glucocorticoid-suppressible hyperandrogenism, 1-2 years of treatment might yield long-term remission 8. However, most hyperandrogenic conditions (like PCOS) will recur upon medication discontinuation 8, 7.

The Bottom Line

Your hormone levels are exactly what we expect with Yasmin plus spironolactone—this represents successful pharmacological suppression, not a new disease process. If you're asymptomatic and not planning pregnancy, continue your current therapy. If you want to reassess your baseline androgen status or plan conception, discontinue both medications for 2-3 months and retest with a high-quality laboratory using LC-MS/MS methodology 9, 10.

References

Guideline

endocrine treatment of transsexual persons: an endocrine society clinical practice guideline.

The Journal of clinical endocrinology and metabolism, 2009

Guideline

american association of clinical endocrinologists medical guidelines for the clinical practice for the diagnosis and treatment of hyperandrogenic disorders.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2001

Guideline

recommendations for investigation of hyperandrogenism.

Annales d'endocrinologie, 2010

Guideline

guidelines of care for the management of acne vulgaris.

Journal of the American Academy of Dermatology, 2024

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.